Key Points
- Neumora President Joshua Pinto sold 5,967 shares on Feb. 17 at an average price of $3.54 (total $21,123), reducing his stake by 9.36% to 57,783 shares; the sale was disclosed in an SEC Form 4 filing.
- The stock traded down about 2.7% to $3.39 on Friday with 364,898 shares changing hands (vs. a ~2.27M average), a 12‑month range of $0.61–$3.65, and a market cap near $565.6M (PE -2.30, beta 3.20).
- Analysts are mixed: several firms recently upgraded price targets and ratings, but the consensus is a "Hold" with an average price target of about $8.13.
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) President Joshua Pinto sold 5,967 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.54, for a total value of $21,123.18. Following the completion of the sale, the president directly owned 57,783 shares of the company's stock, valued at $204,551.82. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Neumora Therapeutics Trading Down 2.7%
Shares of NMRA stock traded down $0.10 on Friday, hitting $3.39. 364,898 shares of the stock traded hands, compared to its average volume of 2,272,368. Neumora Therapeutics, Inc. has a twelve month low of $0.61 and a twelve month high of $3.65. The stock has a market capitalization of $565.60 million, a PE ratio of -2.30 and a beta of 3.20. The firm's 50-day moving average price is $2.18 and its two-hundred day moving average price is $2.06. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Needham & Company LLC increased their price target on Neumora Therapeutics from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Tuesday, October 28th. Royal Bank Of Canada raised Neumora Therapeutics from a "sector perform" rating to an "outperform" rating and raised their price objective for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. William Blair upgraded shares of Neumora Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday. Finally, Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.13.
View Our Latest Stock Analysis on Neumora Therapeutics
Hedge Funds Weigh In On Neumora Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NMRA. AlphaCore Capital LLC acquired a new stake in shares of Neumora Therapeutics during the second quarter worth about $248,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Neumora Therapeutics during the second quarter worth approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Neumora Therapeutics in the 2nd quarter valued at $41,000. Savant Capital LLC purchased a new stake in Neumora Therapeutics in the 2nd quarter valued at $52,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Neumora Therapeutics in the 2nd quarter valued at $42,000. Hedge funds and other institutional investors own 47.65% of the company's stock.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.
Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
